Study links long COVID fatigue to damage of dopamine‑releasing brain neurons

Researchers have identified damage to dopamine‑releasing neurons in the brains of individuals suffering from long COVID, a finding that may account for the condition’s hallmark symptoms of persistent fatigue, reduced motivation, slowed motor function and memory impairment. The study, conducted by a multidisciplinary team of neuroscientists and clinicians, examined post‑mortem brain tissue and neuroimaging data from patients who experienced COVID‑19 infection and continued to exhibit neurological deficits months after recovery. Analyses revealed a statistically significant reduction in the density and activity of dopaminergic neurons within the striatum and prefrontal cortex compared with matched controls, suggesting that the virus—or the immune response it triggers—can disrupt the brain’s dopamine pathways.

The discovery opens a potential therapeutic avenue focused on restoring dopaminergic function. Researchers propose that pharmacological agents known to enhance dopamine signaling, such as selective dopamine agonists or reuptake inhibitors, could alleviate the neurocognitive and motor symptoms associated with long COVID. Ongoing clinical trials are set to evaluate the safety and efficacy of these approaches, while further investigations aim to clarify the mechanisms by which SARS‑CoV‑2 or related inflammatory processes target dopamine neurons. If successful, such interventions may provide targeted relief for millions of patients grappling with the lingering effects of the pandemic.